IMO, this trial is going to enroll quickly across
Post# of 148162
This means:
1. We could see preliminary results by the end of next week (if the FDA allows that).
2. Approval could come within a month if the results are clear, especially when considering the additional results that Dr. Patterson’s tests provide (in addition to clinical improvement).
3. I don’t doubt we’ll see additional IND patients as the demand for the drug is high right now and both phase 2 trials won’t be enough to meet demand.
4. NP and CYDY are certainly working on a pricing and manufacturing plan
5. Revenues are closer than any of us could’ve predicted at the beginning of 2020, but I’m interested to see how pricing goes during a pandemic (especially with the price of drugs being a big point of contention but it’s much less than 21 days in the ICU on a ventilator = saves lives and money.)